Orelabrutinib and MIL62 Combination Therapy Well Tolerated for Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.